Blood Reviews
Volume 26, Issue 1 , Pages 25-32 , January 2012

Chemoimmunotherapy in acute lymphoblastic leukemia

  • Dieter Hoelzer

      Affiliations

    • ONKOLOGIKUM, Frankfurt am Museumsufer, Frankfurt, Germany
    • Corresponding Author InformationCorresponding author at: ONKOLOGIKUM, Frankfurt am Museumsufer, Schaubstr. 16, D-60596 Frankfurt, Germany. Tel.: +49 69 650073 170; fax: +49 69 650073 180.
    • ,
  • Nicola Gökbuget

      Affiliations

    • Department of Internal Medicine II, Hematology and Oncology, Goethe University Hospital, Frankfurt, Germany

References 

  1. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29:532–543
  2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166–178
  3. Gokbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol. 2004;83:201–205
  4. Raponi S, Stefania De Propris M, Intoppa S, Laura Milani M, Vitale A, Elia L, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma. 2011;
  5. Walshe CA, Beers SA, French RR, Chan CH, Johnson PW, Packham GK, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. J Biol Chem. 2008;283:16971–16984
  6. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29:2–9
  7. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242
  8. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113:6330–6337
  9. Maury S, Huguet F, Leguay T, Lacombe F, Maynadie M, Girard S, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica. 2010;95:324–328
  10. Jeha S, Behm F, Pei D, Sandlund JT, Ribeiro RC, Razzouk BI, et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2006;108:3302–3304
  11. Dworzak MN, Schumich A, Printz D, Potschger U, Husak Z, Attarbaschi A, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112:3982–3988
  12. Watt T, Park S, Cooper T. CD20 up-Regulation In Induction Therapy for Childhood B Lymphoblastic Leukemia. Blood. 2010;116:abstract#2124
  13. Dworzak MN, Gaipa G, Schumich A, Maglia O, Ratei R, Veltroni M, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom. 2010;78:147–153
  14. Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Loffler H, Fonatsch C, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87:495–508
  15. Hoelzer D, Goekbuget N, Beck J, Burmeister T, Giagounidis A, Glasmacher A, et al. Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL). Blood. 2004;104:abstract#2732
  16. Rizzieri D, Johnson J, Byrd J, Lozanski G, Powell BL, Shea TC, et al. Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt – Like Leukemia/Lymphoma: Cancer and Leukemia Group B (CALGB) Study 10002. Blood. 2010;116:abstract#858
  17. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–1580
  18. Oriol A, Ribera JM, Bergua J, Gimenez Mesa E, Grande C, Esteve J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer. 2008;113:117–125
  19. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol. 2010;28:3115–3121
  20. Hoelzer D, Huettmann A, Kaul F, Irmer SI, Jaeckel NJ, Mohren M, et al. Immunochemotherapy with rituximab in adult CD20 B-precusor ALL improves molecular CR rate and outcome in standard risk (SR) as well as in high risk (HR) patients with SCT. Haematologica. 2009;94:abstract#481
  21. Hoelzer D, Thiel E, Loffler H, Bodenstein H, Plaumann L, Buchner T, et al. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood. 1984;64:38–47
  22. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3880–3889
  23. Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR, Sklar J, et al. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer. 2003;97:1471–1480
  24. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974–977
  25. Topp M, Goekbuget N, Kufer P, Zugmaier G, Degenhard E, Neumann S, et al. Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study. Blood. 2008;112:abstract#1926
  26. Goekbuget N, Kneba M, Raff T, Trautmann H, Bartram C, Arnold R, et al. Molecular Response Evaluation in Adult Acute Lymphoblastic Leukemia (ALL) – Identification of a New High Risk Group and Reference Data for Future Clinical Trials. Blood 2011, submitted.
  27. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29:2493–2498
  28. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia. 2011;25:181–184
  29. Topp M, Goekbuget N, Zugmaier G, Viardot A, Stelljes M, Neumann S, et al. Clinical Activity of the Anti-CD19 BiTE® Blinatumomab in Patients with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia: Interim Results of a Phase 2 Study. Haematologica. 2011;abstract#844
  30. Stock W, Sanford B, Lozanski G, Vij R, Byrd JC, Powell BL, et al. Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102). Blood. 2009;114:abstract#838
  31. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, et al. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006;106:2645–2651
  32. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol. 2008;26:3756–3762
  33. Morschhauser F, Kraeber-Bodere F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol. 2010;28:3709–3716
  34. Mejstrikova E, Kalina T, Trka J, Stary J, Hrusak O. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy. Leukemia. 2005;19:1092–1094
  35. Golay J, Di Gaetano N, Amico D, Cittera E, Barbui AM, Biondi A, et al. Gemtuzumab Ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukemias in vitro and in vivo. Haematologica. 2005;90(s2):abstract#422
  36. Zwaan CM, Reinhardt D, Jurgens H, Huismans DR, Hahlen K, Smith OP, et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia. 2003;17:468–470
  37. Balduzzi A, Rossi V, Corral L, Bonanomi S, Longoni D, Rovelli A, et al. Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia. 2003;17:2247–2248
  38. Chevallier P, Robillard N, Ayari S, Guillaume T, Delaunay J, Mechinaud F, et al. Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease. Br J Haematol. 2008;143:744–746
  39. Cheung KC, Wong LG, Yeung YM. Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg. Leuk Lymphoma. 2008;49:596–597
  40. Papayannidis C, Derenzini E, Iacobucci I, Curti A, Paolini S, Cilloni D, et al. Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. Am J Hematol. 2009;84:849–850
  41. Frankel AE. New anti-T cell immunotoxins for the clinic. Leuk Res. 2005;29:249–251
  42. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–4402
  43. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol. 2010;28:3525–3530
  44. Seibel NL, Sather H, Steinherz PG, Delaat C, Ettinger LJ, Freyer D, et al. Upfront treatment with B43 PAP immunotoxin in newly diagnosed children with higher risk ALL - Children's Cancer Group 1961. Blood. 2000;96:abstract#3115
  45. Dinndorf P, Krailo M, Liu-Mares W, Frierdich S, Sondel P, Reaman G. Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma. J Immunother. 2001;24:511–516
  46. Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG, et al. Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. Leuk Lymphoma. 1999;33:101–106

PII: S0268-960X(11)00065-8

doi: 10.1016/j.blre.2011.08.001

Blood Reviews
Volume 26, Issue 1 , Pages 25-32 , January 2012

Article Tools